Investigator Meeting – Phase 2 Gates MRI TBD09 study

According to the WHO Global Tuberculosis Report, tuberculosis remains a top infectious killer, with an estimated 1.23 million deaths in 2024, despite it being preventable and curable.
We are ecstatic to have had our staff attend an Investigator Meeting by Gates MRI and IQVIA for an upcoming Phase 2 Gates MRI TBD09 study.
TBD09 emerged from the TB Drug Accelerator, a collaboration among biopharmaceutical companies, the NIH, research organizations and universities, with established support from the Gates Foundation. It aims to establish shorter, more tolerable treatments for TB. We look forward to contributing to these amazing research efforts focused on advancing Tuberculosis treatment and improving patient outcomes.